I've worn a device for a few months and it's clear that the step counts are exaggerated because of arm movements, add up about 50% more I'd say, so real counts would be closer to 2K than the reported 3K. This is surprisingly little, this is about what I was doing (between 2K and 3K) during a period of very low activity being housebound and not doing much.Who the F*** walks 3000 steps a day with me/cfs? And if so, why the hell would you pump that poison in your veins? 3000 steps? Come on people!
Who the F*** walks 3000 steps a day with me/cfs? And if so, why the hell would you pump that poison in your veins? 3000 steps? Come on people!
That suggests you have very severe ME. I'm sorry to hear you are so sick.Difficult to imagine we suffer from the same disease, I cant sit up for 2 mins, for 3 years now.
Exact same here. Although I've since migrated from cardigans to hoodiesMy fitbit counts steps when I put on a cardigan while sitting, and if I lie in bed and move my arm in some ways.
That suggests you have very severe ME. I'm sorry to hear you are so sick.
There is a wide range of severities between people with ME, and within the history of many individuals with ME. My own ME has gone from mild and being able to work part time with great difficulty and lots of crashes, to mostly bedbound. From my experience I'd say I have had the same illness throughout, but at varying severity levels.
I agree a group with an average step count over 3000 sounds like most of them had mild ME. But, as has been pointed out, if the monitors were worn on the arm, that counts arm movements as well, so it's more a movement counter than a step counter. My fitbit counts steps when I put on a cardigan while sitting, and if I lie in bed and move my arm in some ways.
So they could do a blinded multicenter dose response study with maybe 5 different concentration levels of cyclo and maybe anticipate that you would see a response at the higher levels of drug administration, but not at the very lowest levels?
Adverse effects[edit]
In November 2018, the US Food and Drug Administration (FDA) issued a Safety Announcement[5] warning about rare but serious instances of stroke and blood vessel wall tears in multiple sclerosis patients who have received Lemtrada (alemtuzumab), mostly occurring within 1 day of initiating treatment and leading in some cases to permanent disability and even death.
In addition to the 13 cases to which the FDA Safety Announcement refers, a further 5 cases of spontaneous intracranial haemorrhage have been retrospectively identified from four US multiple sclerosis centres in correspondence published online in February 2019.[6]
On 12 April 2019, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported that it has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated conditions and of problems with the heart and blood vessels with this medicine, including fatal cases. PRAC advised that while the review is ongoing, Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies (a type of multiple sclerosis medicine) or where other disease-modifying therapies cannot be used. PRAC further advised that patients being treated with Lemtrada who are benefitting from it may continue treatment in consultation with their doctor.[7]
Very common adverse reactions associated with alemtuzumab infusion in MS patients include upper respiratory tract and urinary tract infections, herpes virus infections, lymphopenia, leucopenia, changes in thyroid function, tachycardia, skin rashes, pruritus, pyrexia, and fatigue.[8] The Summary of Product Characteristics provided in the electronic Medicines Compendium [eMC [9]] further lists common and uncommon adverse reactions that have been reported for Lemtrada, which include serious opportunistic nocardial infections and cytomegalovirus syndrome.[10][11][12]
Alemtuzumab can also precipitate autoimmune disease through the suppression of regulatory T cell populations and/or the emergence of autoreactive B-cells.[13][14]
Cases of multiple sclerosis reactivation/relapse have also been reported[15]
Im surprised theres been so little talk about this publication, 9 people went back to studies/work, and then the rest of the responders might or might not have gotten a placebo effect/other bias, potentially pulling the sf-36 mean score down.
I see so many ME/CFS-studies written about that goes viral, when theres just a random finding being sold as the cause for ME, or treatment x as the cure. Here we actually have a study with objective markers, and apparant prolonged responses, and still I havent seen one article on the net other than from the trust that financed the study.
Are we really that pessimistic after the rituximab-studies?
I was hyped after the Ritxumab trail. I talked to a doctor and paid out of my pocket. It did nothing for me. I followed the autoimmune way over years now for Cfs. I tried MTX, 6 months cortisone, 1 month of sirolimus, 7 plasma exchanges. Im just done with it. The autoimmune part of Cfs is a beaten dead horse to me. Maybe its a part of this disease, maybe its not. Its definitely not useful for a lot of ppl to try and treat it this way. The placebo outcome for the phase 3 ritux trail was better than Cyclo now. So yeah, im not impressed. MTX studies for Cfs made ppl worse overall. ivig studies are all over the place and also mostly negative. I just moved on to look for other ways of treatment than nuking my body with WW1 war crimes. I hope Dr. Prusty's mitochondria study is repeated in another lab soon and i can get my hands on things like SS31 or Mdivi1/P110 and so on.
I don’t know why there hasn’t been much publicity, but from my view I do feel pessimistic after Rituximab. And honestly I’m not generally a pessimistic person. This was trialled on mild or mild/moderate population. A proportion had steps increased after trial - but in ritixumab a similar proportion also seemed to have been helped, which was then shown to be placebo when it got to Stage 3.
People do get better from ME for no reason at all sometimes. I think fluctuating illness is not uncommon. And it doesn’t always have to be due to the drug.
I’m also not so excited because of the fact this is a chemo drug, and chemo even for the normal population - makes them often feel dreadfully ill. So what would it do to those with ME? Particularly severe ME. I understand all drugs have side effects but if it’s a good enough drug it’s worth taking. But as Trish pointed out, ritixumab had similar results at this stage in their trials too. So it doesn’t seem to be a good enough drug.
"A proportion had steps increased after trial - but in ritixumab a similar proportion also seemed to have been helped, which was then shown to be placebo when it got to Stage 3." - We cant say that for sure for the people who got better in the treatment group, but obviously the people in the placebo group got placebo or spontaneous improvement.
"I’m also not so excited because of the fact this is a chemo drug, and chemo even for the normal population - makes them often feel dreadfully ill. So what would it do to those with ME? Particularly severe ME. I understand all drugs have side effects but if it’s a good enough drug it’s worth taking." - Nobody wants this to be a treatment for ME/CFS, but the most important thing is that it due to its non specific immunsuppression could potentially show us that our immune system is key in the disease mechanism. That would narrow research down A LOT
"But as Trish pointed out, ritixumab had similar results at this stage in their trials too. So it doesn’t seem to be a good enough drug." - Again that's looking at the mean. Im more interested in the fact that 9 people returned to study/school. Of all the acquaintances I have made with ME, almost none has returned to school/work. If 9 out of 42 people of my ME-acquaintances did this I would deem it incredible. I would be interested to see the individual data. I wonder how long these people returned, and in what capacity. I might send them a e-mail, why not
@Marky
The "specific antibodies" we know of in Cfs, and you can ask Prof. Edwards he will agree with me, are found in many other diseases as side effects.
Sure everyone needs to go find their own way right now to get better with this awful disease, but when 10 different autoimmune treatments dont work, then either you dont do it hard enough, or, the more likely way, it just isnt an autoimmune disease.
Overall response rates were 35.1% in the placebo for the phase 3 Rituximab trail. And to now get excited about a study thats not blinded, when you know this disease can create crazy placebo rates and daily/weekly/monthly severity swings out of nowhere just isnt for me.
Also we talking about one of the worst medicine you would want to take in your life. Something that just kills everything in your body and just slightly favors the immune system with a high chance of creating cancer down the line. You can see that i tried a lot and wasnt scared about taking a lot of things, heck, right now im trying to get SS31 to experiment with it, that said, i wouldnt touch cyclo with a ten foot pole.